Posted by Michael Wonder on 27 Jan 2024
Highlights from the 22-25 January 2024 CHMP meeting
26 January 2024 - The EMA’s CHMP recommended three medicines for approval at its January 2024 meeting.
The committee recommended granting a marketing authorisation for Exblifep (cefepime/enmetazobactam), for the treatment of complicated urinary tract infections, including pyelonephritis, hospital-acquired pneumonia, including ventilator associated pneumonia, and for the treatment of patients with bacteraemia.
